Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

The study did not provide details on the proportion of patients with therapy-related or secondary acute myeloid leukaemia, and on those with a poor or intermediate-risk karyotype. Complete remission ...

The statistics on this page are for people of all ages who have ALL. We have a separate page about survival for children with cancer. This includes statistics for children with ALL. The terms 1 year ...

There are several types of leukemia, categorized by the speed of progression (acute or chronic) and the type of blood cell affected (lymphocytic or myeloid). The four main types are: Symptoms of ...

This disease is most commonly diagnosed in children, where it accounts for ... Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by excess ...

and to CB-012 for relapsed or refractory acute myeloid leukemia (r/r AML). CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients ...

CB-012 is a product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in the AMpLify Phase 1 clinical trial in patients with relapsed or refractory acute myeloid ...

Sangeetha Venugopal, MD, MS, discusses the dynamic landscape of molecular targets in acute myeloid leukemia. The molecular landscape of acute myeloid leukemia (AML) is constantly changing. Genetic ...